The sodium pump α1 sub-unit: a disease progression–related target for metastatic melanoma treatment

Véronique Mathieu a, Christine Pirker b, Elisabeth Martin de Lassalle c, Mathieu Vernier d, Tatjana Mijatovic d, Nancy DeNeve d, Jean-François Gaussin d, Mischael Dehoux d, Florence Lefranc a, e, Walter Berger b, Robert Kiss a, *

a Laboratory of Toxicology, Institute of Pharmacy, Free University of Brussels (ULB), Brussels, Belgium
b Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
c Pôle de Pathologie, CHRU Lille, France
d Unibioscreen SA, Brussels, Belgium
e Department of Neurosurgery, Erasme University Hospital, Brussels, Belgium

Received: September 25, 2008; Accepted: January 3, 2009

Abstract

Melanomas remain associated with dismal prognosis because they are naturally resistant to apoptosis and they markedly metastasize. Up-regulated expression of sodium pump α sub-units has previously been demonstrated when comparing metastatic to non-metastatic melanomas. Our previous data revealed that impairing sodium pump α1 activity by means of selective ligands, that are cardiotonic steroids, markedly impairs cell migration and kills apoptosis-resistant cancer cells. The objective of this study was to determine the expression levels of sodium pump α sub-units in melanoma clinical samples and cell lines and also to characterize the role of α1 sub-units in melanoma cell biology. Quantitative RT-PCR, Western blotting and immunohistochemistry were used to determine the expression levels of sodium pump α sub-units. In vitro cytotoxicity of various cardenolides and of an anti-α1 siRNA was evaluated by means of MTT assay, quantitative videomicroscopy and through apoptosis assays. The in vivo activity of a novel cardenolide UNBS1450 was evaluated in a melanoma brain metastasis model. Our data show that all investigated human melanoma cell lines expressed high levels of the α1 sub-unit, and 33% of human melanomas displayed significant α1 sub-unit expression in correlation with the Breslow index. Furthermore, cardenolides (notably UNBS1450; currently in Phase I clinical trials) displayed marked anti-tumour effects against melanomas in vitro. This activity was closely paralleled by decreases in cMyc expression and by increases in apoptotic features. UNBS1450 also displayed marked anti-tumour activity in the aggressive human metastatic brain melanoma model in vivo. The α1 sodium pump sub-unit could represent a potential novel target for combating melanoma.

Keywords: melanoma • sodium pump • cMyc • cardenolides • brain metastasis • chemoresistance

Introduction

The incidence of melanoma is steadily increasing with a present lifetime risk of 1 in 50 among the Caucasian population [1]. Melanomas have a strong propensity to metastasize, in particular into the brain, after which they are highly resistant to therapy [2, 3]. Metastatic melanoma patients have only limited treatment options consisting of mono- or poly-therapy with dacarbazine (DTIC), cisplatin and temozolomide (TMZ) [4]. These produce only marginal clinical improvements and have no substantial impact on overall patient survival. Furthermore, even biological/immunotherapy has not contributed greater clinical benefits than DTIC alone [4]. Therefore, new therapeutic approaches are needed [5–8]. We think that targeting the sodium pump (Na+/K+-ATPase) and more specifically its α1 sub-unit could represent a novel means to combat a significant proportion of melanomas. The sodium pump, consisting of α and β sub-units, regulates intracellular ion homeostasis when it is associated with the Na+/Ca2+ exchanger in the plasma membrane [9]. However, when...
located in caveolae and physically associated with caveolin-1 [10], it is no longer concerned with ion homeostasis but is involved in a src-EGFR-controlled signalling complex directly impacting cell proliferation and migration [9, 11]. The natural ligands of the sodium pump are the cardiotonic steroids, which are divided into two chemical groups: cardenolides and bufadienolides [9]. Digitalis compounds (e.g. digoxin, which has been used extensively to treat patients with heart failure) belong to the cardenolide group. The sodium pump α sub-unit acts as a highly selective and sensitive receptor for cardiotonic steroids, whereas the β sub-unit acts as a chaperone for the α sub-unit [9]. There are four α and five β sub-units that have been identified to date. Many cancer types over-express the different α sub-units, including melanoma [12]. α1 sub-units are over-expressed in non-small-cell lung cancer [NSCLC; 13], renal clear cell carcinoma [14] and glioma [10], whereas colon cancer over-express α3 [15]. Inhibiting selectively the expression of the α1 sub-unit in NSCLC [13] and glioma [10] cells markedly impairs both cell proliferation and migration through major disorganization of the actin cytoskeleton, a process that results in lysosomal membrane permeabilization [16] and/or autophagy [10]-related cell death. Metastatic melanomas [17, 18] like glioblastomas [19, 11] are naturally resistant to apoptosis but less to autophagy-related cell death [3, 8, 19].

Over-expression of the cMyc oncogene is also a common feature in melanomas [20–24]. cMyc over-expression in melanomas is associated with a dismal prognosis [21, 22, 25], as well as with resistance to chemotherapy [23, 24] and radiotherapy [20]. Impairing cMyc expression in melanoma cells forces them to undergo apoptosis [5, 26]. Targeting the sodium pump α1 sub-unit markedly impairs cMyc expression, at least in human prostate cancer cells [9]. Taken together, these data prompted us to investigate the levels of expression of the sodium pump α1 sub-unit in a human clinical series of naevi and melanomas and in experimental human melanoma models. We then analyzed the consequences of inhibiting sodium pump α1 sub-unit activity (using anti-α1 siRNA and cardiotonic steroids) in relation to cMyc expression levels and the impact on cell proliferation and death in various experimental melanoma models. The potential use of cardenolides for melanoma treatment was also investigated in human brain experimental melanoma models. The potential use of cardenolides levels and the impact on cell proliferation and death in various siRNA and cardiotonic steroids) in relation to cMyc expression

Primary cell cultures
Primary melanoma cell cultures (VM-1, 7, 10, 21, 23, 24, 28, 30, 47 and 48) were established at the Institute of Cancer Research, Medical University of Vienna, as previously described [28]. Briefly, surgical specimens confirmed by histocytology as primary or metastatic melanoma lesions were blended mechanically and transferred into culture flasks containing growth medium (RPMI 1640, 20% foetal calf serum (FCS), 1% glutamine and 1% penicillin/streptomycin; PAA Laboratories, Linz, Austria). After passage 3, cells were cultured in growth medium containing 10% FCS and 1% glutamine but without antibiotics. The melanocyte origin of the tumour cell cultures was confirmed by electron-microscopy through the presence of melanosomes as well as immunocytochemically by S100 and HMB 45 antigen detection, and biochemically by melanin and tyrosinase determination.

Compounds
Temozolomide (TMZ) was purchased from Schering Plough (Brussels, Belgium), dacarbazine and taxol from Teva Pharma (Wiltirik, Belgium), cisplatin, digoxin and heliellbrin from Sigma-Aldrich (Bornem, Belgium), ouabain and digitoxin from Acros Organics (Gee, Belgium) and UNBS1450 was hemi-synthetized at Unibioscreen SA (Brussels, Belgium) as detailed previously [29].

Clinical samples
Immunohistochemical expression of sodium pump α1 sub-units was determined on a series of 139 clinical samples, including 57 naevi and 82 melanomas (Table 1). Samples were obtained from the Pôle de Pathologie (CHR Lille Hospital, France) and the Erasmus University Hospital (Brussels, Belgium), the latter providing six melanoma metastases for the quantitative determination of mRNA expression of sodium pump α1, α2 and α3 sub-units, as described previously [10].

In vivo xenografts
In vivo xenografts of human melanoma VM-48 cells in nude mice were obtained as described previously in the case of glioma models [30, 31]. All mice (6-week-old female nu/nu mice; 21–23 g; Ita Credo, Charles Rivers, Arbesle, France) in the study had 1 × 10⁵ VM-48 cells stereotactically implanted into the brain on the same day. Each experimental group contained 11 mice. The in vivo experiment described in the present study was performed on the basis of Authorization no. LA1230509 of the Animal Ethics Committee of the Federal Department of Health, Nutritional Safety and the Environment (Belgium).

Determination of sodium pump α1 sub-unit immunohistochemical expression
Immunohistochemical analysis of the 139 clinical samples (Table 1) was performed as detailed previously [13]. The primary antibody against the sodium pump α1 sub-unit was obtained from Upstate (Millipore, Brussels, Belgium; dilution 1/400). The positive tissue sample was normal human kidney. The semi-quantitative analysis was performed by a specialized pathologist and assessed in terms of the percentage of area stained and the intensity of staining (0: no staining, +: low staining, ++: marked staining).

Materials and methods

Cell cultures and compounds

Established cell lines
The human HT-144 (ATCC code HTB-63), G-361 (ATCC code CRL-1424), C-32 (ATCC code CRL-1585) and SKMEL-28 (ATCC code HTB-72) melanoma cell lines and the mouse B16F10 (ATCC code CRL-6475) melanoma cell line were obtained from the American Type Culture Collection (ATCC; Manassas, VA) and maintained in our laboratory as detailed previously [7, 27].
Quantitative reverse transcriptase–polymerase chain reaction (qRT-PCR)

qRT-PCR analyses were performed as detailed previously [10] to determine the levels of mRNA expression of the sodium pump α1, α2 and α3 sub-units in 6 human melanoma metastases and in 14 human melanoma cell lines.

Transient transfection with sodium pump anti-α1 siRNAs

A sodium pump anti-α1 siRNA with sense 5’-GGGCAGUGUU-CAGGCUA-3’ and anti-sense 5’-UUAGCCUGAAACACUGCCC-3’ was used that had already revealed itself to be highly efficient in reducing α1 expression in NSCLC [13] and glioma [10] cells. The control (scrambled) siRNA was sense 5’-UCUACGAGGCACGAGACUU-3’ and anti-sense 5’-AACUCUGACGUAGA-3’ [10, 13]. The melanoma cells were transfected twice consecutively (on days 0 and 1) with the Profection Mammalian Transfection System® (Promega, Leiden, The Netherlands) according to the manufacturer’s instructions as previously detailed [7]. Transfecting melanoma cells with anti-α1 siRNA twice on two consecutive days resulted in a decrease of at least 60% in target expression that lasted for at least 3 days, a result not obtained when transfecting the cells only once. The final concentration of the siRNAs applied overnight to the cells for the transfections was 20 nM.

Protein expression measurements

Western blot and immunofluorescence analyses were performed as detailed previously [7, 16, 27, 32]. Negative controls included the omission of the incubation step with primary antibodies. For Western blotting, the integrity and equal loading of the extracts were assessed by means of histone 3 or tubulin immunoblotting. The primary antibodies used for protein level determination, either by Western blot or by immunofluorescence, were as follows: α1 antibody (dilution 1/200 for immunofluorescence and 1/1000 for Western blotting; Upstate), cMyc antibody (1/50 for immunofluorescence and 1/400 for Western blotting; Santa Cruz, Heidelberg, Germany), anti-PARP (poly (ADP-ribose) polymerase) antibody (dilution 1/250; Calbiochem, VWR, Leuven, Belgium), tubulin antibody (dilution 1/200; Abcam, Cambridge, UK) and histone H3 antibody (1/1000; Cell Signaling, Bioké, Leiden, The Netherlands). Secondary antibodies were purchased from Pierce (PerbioScience, Erembodegem, Belgium) for the Western blots and from Molecular Probes (Invitrogen, Merelbeke, Belgium) for fluorescent detection (Alexa fluor conjugated antibodies). Western blots were developed using the Pierce Supersignal Chemiluminescence system.

Table 1 Immunohistochemical expression of α1 sub-units in clinical naevi and melanoma samples

| Diagnosis | Histological or clinical data | No. of cases analyzed | No. of positive cases | Staining intensity | Area stained (%) |
|-----------|-------------------------------|-----------------------|-----------------------|--------------------|------------------|
|           |                               |                       |                       | +                  | ++               |
| Naevi     | Dermal                        | 20                    | 2/20                  | 2                  | 0                |
|           | Junctional                    | 11                    | 0/11                  | 0                  | 0                |
|           | Mixt                          | 23                    | 1/23                  | 1                  | 0                |
|           | Lentigo                       | 3                     | 0/3                   | 0                  | 0                |
| Total     |                               | 57                    | 3/57                  | 3                  | 0                |
| Melanomas | SSM                           | 26                    | 5/26                  | 1                  | 4                |
|           | NM                            | 3                     | 1/3                   | 1                  | 0                |
|           | Acral                         | 5                     | 1/5                   | 1                  | 0                |
|           | Dubreuil                      | 10                    | 1/10                  | 1                  | 0                |
| Metastases| Lymph nodes                   | 9                     | 2/9                   | 0                  | 2                |
|           | Brain                         | 18                    | 13/18                 | 1                  | 12               |
|           | Others                        | 11                    | 4/11                  | 2                  | 2                |
| Breslow   | <1 mm                         | 18                    | 0/18                  | 0                  | 0                |
|           | 1–2 mm                        | 8                     | 1/8                   | 1                  | 0                |
|           | 2–4 mm                        | 8                     | 3/8                   | 1                  | 2                |
|           | >4 mm                         | 10                    | 4/10                  | 2                  | 2                |
| Total     |                               | 82                    | 27/82                 | 7                  | 20               |

Table 1 Immunohistochemical expression of α1 sub-units in clinical naevi and melanoma samples

3962 © 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Determination of apoptosis

Apoptosis was determined by means of flow cytometry using double annexin V–propidium iodide staining, as detailed elsewhere [33] using the APO AF apoptosis detection kit (Sigma-Aldrich) following the manufacturer’s instructions. Poly ADP ribose protein (PARP: 116 kD) is differentially cleaved into 83–89 kD fragments during apoptosis or into 50–60 kD fragments during necrosis. The expression of native and cleaved proteins was evaluated by Western blot using the Calbiochem antibody (see Protein Expression Measurements section) as previously described [7].

In vitro overall growth determination

Overall cell growth was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) colorimetric assay, as detailed elsewhere [10, 29]. All determinations were carried out in sextuplicate.

Computer-assisted phase-contrast microscopy (quantitative videomicroscopy)

Quantitative videomicroscopy was performed as detailed previously [10, 13]. Briefly, 25 cm² flasks were placed under phase-contrast microscopes located in temperature-controlled incubators for 72 hrs. During this time period, pictures of the same fields were taken every 4 min., thanks to computer assistance. Based on these pictures, we calculated for each cell line and each experimental treatment the global growth rate (GGR), which corresponded to the ratio of the mean number of cells present in the last image captured in the experiment (at 72 hrs) to the number of cells present in the first image (at 0 hr). Furthermore, the 1080 pictures obtained during the 72 hrs of observation were accelerated to give a short film (1 min.) allowing us to observe and monitor the morphological changes and cell migration trajectories induced by the various treatments. Each condition was evaluated in triplicate.

Statistical analyses

Statistical comparison of the expression of sodium pump α1 sub-units between naevi and melanoma groups was undertaken using Fisher’s exact test. The comparison of the Breslow levels in negative versus positive α1 stained melanoma samples was conducted by the Mann–Whitney test. Survival analyses were carried out by means of Kaplan–Meier curves and Gehan’s generalized Wilcoxon test (see Protein Expression Measurements section) as previously described [7].

Results

Characterization of sodium pump α1 sub-unit expression in clinical samples and experimental models of melanoma

Table 1 details the pattern of sodium pump α1 sub-unit expression in a series of 57 naevi and 82 melanomas. The data show that only 3 out of 57 (approximately 5%) naevi display significant immunohistochemical expression of α1 sub-units, whereas 27 out of 82 (33%) of the melanomas were positive for α1 sub-units ($P < 0.01$). Among the melanoma samples, the Breslow index was significantly higher ($P = 0.003$) in the α1 sub-unit positive cases (mean Breslow: 6.1 mm) compared with the α1 sub-unit negative cases (mean Breslow: 2.5 mm). Furthermore, 7 out of 18 (39%) melanomas with a Breslow index greater than 2 mm were immunohistochemically positive, whereas this was the case for only 1 out of 27 (4%) when the Breslow index was lower than 2 mm. With regard to melanoma metastases, it is worth noting that 50% were immunohistochemically positive for the α1 sub-unit and the value was 72% for brain metastases, whose treatment still remain a real challenge.

Table 2 details the IC_{50} values obtained with respect to three anti-melanoma cytotoxic agents, dacarbazine, cisplatin and temozolomide, against 10 human melanoma primary cell cultures, 4 human established melanoma cell lines and 1 mouse melanoma cell line. In addition, use was also made of taxol because although it is not a first-line treatment for melanoma cell lines and 1 mouse melanoma cell line. In addition, use was also made of taxol because although it is not a first-line treatment for melanoma patients, it nevertheless remains one of the most potent anti-cancer drugs available. The IC_{50} value represents the concentration of the drug that inhibits 50% of the in vitro global growth of a cell line after 3 days’ incubation. Table 2 also details the IC_{50} values obtained with five sodium pump α sub-unit antagonists (cardiotonic steroids), including four cardenolides: ouabain, digoxin, digitoxin [9] and one semi-synthetic derivative of 2’-oxovoroscarin [UNBS1450: 29], and one bufadienolide: hellebrin [9]. The data in general show that cardiotonic steroids display higher inhibitory effects on the global growth of human melanoma cells than conventional cytotoxic drugs, and of the four cardenolides, UNBS1450 displayed the most pronounced anti-cancer effects. In contrast, conventional cytotoxic drugs and cardiotonic steroids, with the exception of taxol (IC_{50}: 8 nM), were inactive against mouse B16F10 cell line. Figure 2A illustrates the effects of 100 nM digoxin or UNBS1450 treatment after 72 hrs on VM-21 melanoma cell morphology. UNBS1450 markedly impaired both VM-21
cell proliferation and migration with dramatic cell shrinkage (see the white arrows in Fig. 2Ad), a feature not observed with digoxin (Fig. 2Ab). This impairment in VM-21 cell proliferation and migration was morphologically reproduced using the anti-α1/H9251 siRNA (see the white arrows in Fig. 2Bc). The effects observed with the anti-α1 siRNA were less pronounced than with UNBS1450 because the siRNA used did not totally eliminate α1 expression as further illustrated in Figs. 2Bd and 4B.

The GGR values were calculated as detailed above for each drug treatment (i.e. digoxin and UNBS1450) and cell type, and results expressed as the ratio between the treatment GGR values and the control GGR values on the x axis of Fig. 2C. Horizontal lines in Fig. 2C join the two drug treatments performed on a given cell line. The effects of 100 nM UNBS1450 (black circles) compared with 100 nM digoxin (open circles) on the GGRs of 10 human melanoma primary cell cultures and 4 established cell lines after 72 hrs of exposure to each compound were greatly more marked with the former (Fig. 2C). UNBS1450 almost completely blocked cell proliferation in the cell lines and primary cell cultures and the anti-cancer effects of the two compounds reflected in their GGR ratios (Fig. 2D). This may relate to the high amounts of α1 sub-units in the melanoma cell lines studied (1 to 8 x 10^6 mRNA copies/ng cDNA).

The in vitro anti-cancer efficacy of sodium pump α1 sub-unit inhibitors directly relates to their efficiency in decreasing cMyc expression

Changes in cell morphology were used to determine time-dependent anti-cancer effects of four cardiotonic steroids (UNBS1450 [UNBS], ouabain [OUA], digoxin [DIGO] and digitoxin [DIGI]) in five melanoma cell lines (VM-21, VM-24, C32, SKMEL-28 and B16F10). Typical illustrations of the anti-cancer effects over 72 hrs are given in Fig. 3 with respect to UNBS1450, the compound that induced the greatest changes in cell morphology. In these experiments, anti-tumour effects were determined to have occurred when more than 50% of melanoma cells present in the cultures presented a ‘rounded shape’ and ‘scrunched’ appearance, which is associated with impairment of both migration and proliferation [10, 13, 32]. Such marked morphological changes were not obtained with the three other cardenolides: ouabain, digoxin and digitoxin (data not shown). Previous work in NSCLC [13] and glioma [10] cell lines had already demonstrated that once tumour cells treated with cardiotonic steroids reach this rounded-shape stage, they irreversibly die from lysosomal membrane permeabilization-related and/or autophagy-related cell death. The rounded-shape morphology induced by cardiotonic steroid treatment is the result of a major disorganization of the actin cytoskeleton due to a dramatic drop in intracellular ATP. This actin disorganization impairs both
| Cell line | Origin | DTIC | Cisplatin | Taxol | TMZ | Ouabain | Digitoxin | Digoxin | UNBS1450 | Hellebrin |
|----------|--------|------|-----------|-------|-----|---------|-----------|---------|----------|----------|
| VM-10    | SSM    | >10,000 | 9877     | >10,000 | >10,000 | 79   | 99   | 240   | 25   | 90   |
| VM-30    | SSM    | >10,000 | >10,000 | >10,000 | >10,000 | 333  | 473  | 1475  | 45   | 703  |
| VM-7     | NM     | >10,000 | 3475     | 69    | >10,000 | 22   | 36   | 56    | 5    | 64   |
| VM-21    | NM     | >10,000 | 9012     | 46    | >10,000 | 39   | 58   | 94    | 8    | 86   |
| VM-23    | NM     | >10,000 | 10,000   | 112   | >10,000 | 69   | 326  | 444   | 23   | 273  |
| VM-1     | LN     | >10,000 | >10,000 | >10,000 | >10,000 | 122  | 234  | 446   | 35   | 518  |
| VM-24    | LN     | >10,000 | 3139     | 4     | >10,000 | 43   | 46   | 270   | 29   | 921  |
| VM-28    | BM     | >10,000 | >10,000 | 1000  | >10,000 | 7    | 91   | 350   | 12   | 326  |
| VM-47    | BM     | >10,000 | 6687     | 209   | >10,000 | 172  | 236  | 348   | 10   | 41   |
| VM-48    | BM     | >10,000 | 9498     | 36    | >10,000 | 70   | 228  | 419   | 23   | 273  |
| HT-144   | MM     | >10,000 | 10,000   | 13    | >10,000 | 76   | 263  | 3786  | 353  | 900  |
| G-361    | PM     | 9414    | 10,000   | 50    | >10,000 | 90   | 62   | 331   | 48   | 51   |
| C-32     | PM     | >10,000 | 10,000   | >10,000 | >10,000 | 103  | 63   | 455   | 49   | 100  |
| SKMEL-28 | PM     | >10,000 | >10,000 | >10,000 | >10,000 | 280  | 1754 | 467   | 76   | 101  |
| B16F10   | PM     | >10,000 | 9396     | 8     | ~5000  | >10,000 | >10,000 | >10,000 | 4499 | 2800 |

**Table 2** *In vitro* compound-induced anti-growth effects on melanoma cells expressed as IC50 values

IC50 (nM) values obtained using the MTT assay. Data are expressed as means; S.E.M.s are less than <5% of the mean values in all cases.

Abbreviations: SSM, superficial spreading melanoma; NM, nodular melanoma; LN, lymph node melanoma metastasis; BM, brain melanoma metastasis; MM, metastatic melanoma; PM, primary melanoma; DTIC, dacarbazine; TMZ, temozolomide; NA, not applicable.
cell proliferation (cytokinesis) and migration as already demonstrated for NSCLC [13], glioma [10] and prostate cancer [32] cells, and is associated with marked decreases in cMyc expression [32]. In these experiments in which the compounds were incubated at 100 nM, UNBS1450 proved to inhibit cell growth in human cell lines VM-21, VM-24, C32 and SKMEL-28 but not in mouse B16F10 consistent with IC50 data reported in Table 2 (5–76 nM versus 4499 nM, respectively).

After 15 hrs of incubation of VM-21 cells with 100 nM UNBS1450, most of these melanoma cells were of a rounded appearance, and Western blot analysis revealed cMyc expression to have been almost completely abolished; a feature not observed with the remaining three cardiotonic steroids. Similarly, UNBS1450 was more effective in decreasing cMyc expression in this cell line than the other cardenolides when used at 10 nM (Fig. 3). With respect to VM-24 and C32 cells, the majority achieved the rounded appearance at 33 hrs, whereas at 15 hrs only a minority of these cells had undergone this change. Accordingly, the effects of 100 nM UNBS1450 on cMyc expression at 15 hrs in VM-24 and C32 cells were less marked than those observed in VM-21 cells. However, UNBS1450 decreased cMyc expression in VM-21, VM-24 and C32 melanoma cells in a more pronounced manner than the remaining three cardenolides (Fig. 3). SKMEL-28 melanoma cells remained apparently healthy for the first 15 hrs of treatment with 100 nM UNBS1450, and accordingly there was no decrease in cMyc expression at 15 hrs, although by 72 hrs, cells showed the characteristic rounded appearance. This slower effect may relate to the higher UNBS1450 IC50 value against SKMEL-28 melanoma cells (76 nM) compared with that for VM-21 cells (8 nM; Table 2). As expected, given the very high IC50 values against mouse melanoma B16F10 for UNBS1450 and the other cardenolides studied (Table 2), no effect on cMyc was demonstrated in this cell line.

Fig. 2 Cardenolide and anti-α1 siRNA effects on melanoma cells. (A) First (0 hr) and last (72 hrs) images of the videomicroscopic analysis of the effects of the cardenolides: digoxin (Aa & Ab) or UNBS1450 (Ac & Ad) both incubated at 100 nM on VM-21 melanoma cells. White arrows indicate the cell shrinkage induced by UNBS1450 treatment. (B) Light microscopy images of VM-21 cells transfected either with scrambled siRNA as a control (Ba) or with a sodium pump anti-α1 siRNA (Bc). The pictures were taken 3 days after the first transfection. Cell shrinkage was also evident in the anti-α1 siRNA transfected cells as indicated in the right corner panel. Immunofluorescent staining revealed a partial decrease in the expression of α1 sub-units in anti-α1 siRNA transfected VM-21 cells (Bd) compared with scrambled siRNA-transfected cells (Bb). (C) Global growth rates (GGR) over 72 hrs for each of the 14 melanoma cell lines evaluated were calculated on the basis of the videomicroscopic images generated under control or compound-treated conditions (see Materials and Methods). The data reported illustrate the relationship between the ratio of the compound-treated GGR values to the control GGR values on the x axis and the control GGR values (y axis). Each cell line is represented by two joined circles: the white ones relate to the digoxin (100 nM) ratio, whereas the black ones relate to the UNBS1450 (100 nM) ratio. A significant correlation fit was obtained for the UNBS1450 response. (D) Attempted correlation between the ratios of the GGR values (same x axis as in C) and the number of sodium pump α1 sub-unit mRNA copies present in each of the 14 melanoma cell lines. No correlation is evident.
The data in Fig. 4A further confirm a rapid and sustained decrease in cMyc expression level in VM-21 cells when treated with 100 but not 10 nM UNBS1450, even after 3 hrs, whereas no such consistent decrease could be obtained in the SKMEL-28 cells even after 48 hrs of treatment. It thus seems possible that the early determination of cMyc down-regulation of expression (e.g. in vitro 15 hrs after the beginning of compound treatment) may enable one to predict whether a given melanoma cell line will be sensitive to the anti-cancer effects of cardiotonic steroids. Furthermore, cardiotonic steroid-mediated decreases in cMyc expression seem to result at least partly, from the inhibition of sodium pump \( \alpha_1 \) sub-unit expression and/or activity as assessed by the use of the anti-\( \alpha_1 \) siRNA in VM-21 melanoma cells (Fig. 4B).

**Characterization of UNBS1450-induced effects on apoptosis**

Use was made of highly cardenolide-sensitive VM-21 and more cardenolide-resistant SKMEL-28 melanoma cells for apoptosis assays: annexin V/prodium iodide staining and PARP (poly ADP ribose protein) cleavage analysis. Cells were exposed to UNBS1450 for 15 hrs to 40 hrs. After 15 hrs, the data show marked late apoptosis staining revealed by flow cytometry in VM-21 cells following 50 and 100 nM UNBS1450 treatment but effects were markedly less pronounced at 10 nM (Fig. 5Ab and Ba). This result was further validated by PARP cleavage analysis, evidencing characteristic apoptotic fragments notably at 100 nM after 24 hrs (Fig. 5Ca). Although a few populations of SKMEL-28 cells displayed apoptotic features in flow cytometry (Fig. 5Bb), even after 40 hrs of treatment with 100 nM UNBS1450 (Fig. 5Bb), PARP cleavage analysis did not indicate any apoptosis (Fig. 5Cb). Thus, the more resistant SKMEL-28 cells do not seem to undergo apoptotic programmed cell death following 100 nM UNBS1450 treatment. The marked decrease in cMyc expression in VM-21 cells induced by the sodium pump sub-unit targeting approach (Fig. 4) could therefore provoke a cMyc-dependent cellular crisis leading in turn to apoptosis [26], whereas UNBS1450 seems to kill SKMEL-28 cells via other cell death pathways.

**Fig. 3** Morphological changes in melanoma cells and their expression of cMyc on incubation with cardenolides. The left panel illustrates the morphological changes seen in different melanoma cell lines (annotated on the left) over 72 hrs when incubated with 100 nM UNBS1450. Human VM-21 cells are the most sensitive, whereas the mouse B16F10 model is completely resistant to the treatment. The right panel corresponds to Western blot analysis of cMyc expression levels in each cell line after 15 hrs of exposure to four different cardenolides (UNBS: UNBS1450, OUA: ouabain, DIGO: digoxin and DIG I: digitoxin) at 10 and 100 nM. Although cMyc is down-regulated after UNBS1450 treatment (100 nM) in the VM-21, VM-24 and C32 responding cell lines, this is not the case in the poorly responding or non-responding SKMEL-28 and B16F10 cells. Tubulin or histone H3 blots were used as the loading controls.
UNBS1450 improves the survival of immuno-deficient mice bearing human melanoma brain metastases

Given the high expression of sodium pump α1 sub-units in melanoma brain metastases, we investigated whether cardenolides could bring any therapeutic benefits to a new human melanoma brain metastases model. VM-48 cells, originating from human brain melanoma metastases, grafted directly into the brain of immuno-deficient nude mice produced typically invasive brain metastases as indicated in Fig. 6A and B. These VM-48-bearing mice were treated with either reference drugs: dacarbazine (80 mg/kg i.p.) or temozolomide (40 mg/kg i.v.) or with the novel cardenolide UNBS1450 (1 mg/kg i.v.). All drug treatments started 7 days after tumour grafting and employed a schedule of three injections per week (Monday, Wednesday and Friday) for three consecutive weeks. Figure 6C illustrates the survival of animals over time and reveals that in contrast to UNBS1450 (P < 0.01), neither dacarbazine nor temozolomide could bring any significant therapeutic benefit (P > 0.05).

Discussion

Ion channels and transporters play crucial roles in mediating a variety of physiological and pathological processes of cell biology [34]. For example, cell shape and volume changes are of crucial importance in aiding glioma cell migration because extracellular spaces in the brain are very narrow and represent a major obstacle that forces glioma cells to dynamically regulate their volume [35]. Pharmacological inhibition of Cl− channels in glioma cells impairs their ability to migrate and limits tumour progression in experimental tumour models [35]. One Cl−-channel inhibitor, chlorotoxin, has already reached Phase I clinical trials with the goal to treat malignant glioma [34]. K+ channel-dependent migration of B16 mouse [34] and human [36] melanoma cells has also been demonstrated. We have recently demonstrated that the sodium pump α1 sub-unit plays a crucial role in NSCLC [13, 16], glioma [10] and prostate cancer [32] cell biology, all without impacting Na+ and K+ exchange [10]. In fact, inhibiting the activity of the sodium pump α1 sub-unit sharply decreases intracellular ATP concentrations [10, 32], a process known to markedly disorganize the actin cytoskeleton [37], which in turn impairs both proliferation (at the level of cytokinesis) and migration. Inhibiting the activity of α1 sub-units is also known to result in dramatic cancer cell shrinkage [10, 13, 32], a phenomenon observed in the current study in a significant number of melanoma models (Fig. 3). It seems that it is actually α1 and not other α sub-units that are implicated in cardiotonic steroid-induced anti-tumour effects in melanoma cells given that (i) inhibiting α1 expression, even partly, by means of siRNA reproduces the effects observed with a selective α1 sub-unit antagonist, such as UNBS1450 (Fig. 2); (ii) only the α1 sub-unit is expressed in all human melanoma models studied (Fig. 1) and (iii) rodent tumour cells in which the sodium pump α1 sub-unit is twice mutated [32] leads to a 1000-fold decrease in sensitivity towards cardiotonic steroid-mediated anti-cancer effects when compared with human cancer cells [10, 13]. The latter was also observed in the current study with respect to the B16F10 mouse melanoma cells (Fig. 3 and Table 2).
Analysis of clinical samples by semi-quantitative immunohistochemistry revealed that more than 30% of all human melanomas, 50% of all melanoma metastases and 72% of brain melanoma metastases over-expressed sodium pump \( \text{Na}^+\text{K}^+\text{ATPase} \) sub-units compared with only 5% of naevi (Table 1). \( \alpha_1 \) Sub-unit expression significantly correlates with tumour thickness and disease progression. Furthermore, with respect to the \( \alpha_1 \) mRNA data obtained in the present study and the results that Boukerche et al. [12] reported in an earlier study, these values may even be underestimates given the immunohistochemical method used.

The in vivo data from the present study strongly suggest that targeting the sodium pump \( \alpha_1 \) sub-unit by using novel cardenolides such as UNBS1450 could bring greater clinical effectiveness in combating this cancer, in particular brain metastatic melanomas whose treatment still represents one of the biggest challenges in melanoma therapy. This statement is made given the activity of UNBS1450 in the particularly aggressive melanoma model studied, when neither of the two compounds used currently in clinical practice, dacarbazine and temozolomide [8], produced statistically significant activity in this model.

As already emphasized in the introduction, cMyc is an important player in melanoma biology aggressiveness [5, 21, 22, 23, 25, 26]. The data from the present study strongly suggest that UNBS1450 exerts part of its anti-cancer effects in melanoma cells through decreases in cMyc expression (Fig. 3). We recently showed in human prostate cancer cells that UNBS1450 mediates anti-tumour effects in part through the compound’s capacity to disorganize nucleolar structure and to impair CDK and cMyc expression and related signalling pathways [32]. Inhibition of cMyc expression in melanoma cells induces cellular crisis through co-operation between telomerase dysfunction and oxidative stress [26]. Cellular crisis is defined as an increase in cell size, multiple nuclei, vacuolated cytoplasm, induction of senescence-associated \( \beta \)-galactosidase activity and massive apoptosis [26]. The data...
UNBS1450 could kill SKMEL-28 cells via lysosomal membrane permeabilization-related cell death as suggested in the in vivo data reported here.
References

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71–96.
2. Onken MD, Worley LA, Ehlers JP, et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004; 64: 7202–9.
3. Lefranc F, Facchini V, Kiss R. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist. 2007; 12: 1395–405.
4. Jaeger J, Koczan D, Thiesen HJ, et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res. 2007; 13: 806–15.
5. Pastorino F, Brignole C, Marimpietri D, et al. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin Cancer Res. 2003; 9: 4595–605.
6. Lejeune FJ, Rimoldi D, Speiser D. New approaches in metastatic melanoma: biological and molecular targeted therapies. Expert Rev Anticancer Ther. 2007; 7: 701–13.
7. Mathieu V, Le Mercier M, De Neve N, et al. Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 anti-cancer therapy. BBA Rev Cancer. 2008; 1776: 32–57.
8. Tawbi HA, Kirkwood JM. New approaches in metastatic melanoma: biological and molecular targeted therapies. Expert Rev Anticancer Ther. 2007; 7: 701–13.
9. Lejeune FJ, Rimoldi D, Speiser D. New approaches in metastatic melanoma: biological and molecular targeted therapies. Expert Rev Anticancer Ther. 2007; 7: 701–13.
10. Lefranc F, Mijatovic T, Kondo Y, et al. Cardiotoxic steroids on the road to anti-cancer therapy. BBA Rev Cancer. 2007; 1776: 32–57.
11. Lefranc F, Mijatovic T, Kondo Y, et al. Targeting the alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. J Pathol. 2007; 212: 170–9.
12. Seligson DB, Rajasekaran SA, Yu H, et al. Na,K-adenosine triphosphatase alpha1-subunit predicts survival of renal clear cell carcinoma. J Urol. 2008; 179: 338–45.
13. Sakai H, Suzuki T, Maeda M, et al. Up-regulation of Na(+),K(+)-ATPase alpha-3 isoform and down-regulation of the alpha-1 isoform in human colorectal cancer. FEBS Lett. 2004; 563: 151–4.
14. Mijatovic T, Mathieu V, Gaussin JF, et al. Cardiotoxic-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia. 2006; 8: 402–12.
15. La Porta CA. Drug resistance in melanoma: new perspectives. Curr Med Chem. 2007; 14: 387–91.
16. Hersey P, Zhuang L, Zhang XD. Current strategies in overcoming resistance of cancer cells to apoptosis: melanoma as a model. Int Rev Cytol. 2006; 251: 131–58.
17. Lefranc F, Brochli J, Kiss R. Possible future issues in the treatment of glioblastomas: specific emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol. 2005; 23: 2411–22.
18. Buco B, D’Agnano I, Amendola D, et al. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins. Clin Cancer Res. 2005; 11: 2756–67.
19. Grover R, Chana J, Grobbelaar AD, et al. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma. Br J Plast Surg. 1999; 52: 122–6.
20. Ramsden AJ, Grover R, Chana J, et al. A prospective analysis of c-myc oncoprotein levels as a prognostic marker in malignant melanoma. J Plast Reconstr Aesthet Surg. 2007; 60: 626–30.
21. Tulley PN, Neale M, Jackson D, et al. The relationship between c-myc expression and interferon sensitivity in uveal melanoma. Br J Ophthalmol. 2004; 88: 1563–7.
22. Zupi G, Scarsella M, Semple SC, et al. Antitumor efficacy of bcl-2 and c-myc anti-sense oligodeoxynucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence. Clin Cancer Res. 2005; 11: 1990–8.
23. Schlagbauer-Wadl H, Griffioen M, van Elsas A, et al. Influence of increased c-Myc expression on the growth characteristics of human melanoma. J Invest Dermatol. 1999; 112: 332–6.
24. Biocchio A, Amodei S, Antonelli A, et al. Inhibition of c-Myc oncoprotein limits the growth of human melanoma cells by inducing cellular crisis. J Biol Chem. 2003; 278: 35693–701.
25. Mathieu V, Mijatovic T, van Damme M, et al. Gastrin exerts pleiotropic effects on human melanoma cell biology. Neoplasia. 2005; 10: 930–43.
26. Berger W, Hauptmann E, Elbling L, et al. Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells. Int J Cancer. 1997; 71: 108–15.
27. Van Quaquebeke E, Simon G, André A, et al. Identification of a novel cardenolide (2”-oxovorosucarin) from Calotropis procera and the hemisynthesis of novel derivates displaying potent in vitro antitumor activities and high in vivo tolerance: structure-activity relationship analyses. J Med Chem. 2005; 48: 849–56.
28. Brande F, Lefranc F, Camby I, et al. Evaluation of the efficacy of chemotherapy in vivo in orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer. 2002; 95: 641–55.
29. Lefranc F, Mijatovic T, Mathieu V, et al. Characterization of gastrin-induced proangiogenic effects in vivo in orthotopic U8737 experimental human glioblastomas and in vitro in human umbilical vein endothelial cells. Clin Cancer Res. 2004; 10: 8250–65.
30. Mijatovic T, De Nëve N, Gailly P, et al. The nucleoside and c-Myc: potential targets of cardenolide-mediated anti-tumor activity. Mol Cancer Ther. 2008; 7: 1285–96.
31. Dumont P, Ingrassia L, Rouzeau S, et al. The Amaryllidaceae isocarbostyril narcissamine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia. 2007; 9: 766–76.
32. Liu YL, Hu CL, Ma LJ, et al. ET-1 inhibits B-16 murine melanoma cell migration by decreasing K(+) currents. Cell Motil Cytoskeleton. 2004; 58: 127–36.
35. McFerrin MB, Sontheimer H. A role for ion channels in glioma cell invasion. Neuron Glia Biol. 2006; 2: 39–49.

36. Schwab A, Reinhardt J, Schneider SW, et al. K(+) channel-dependent migration of fibroblasts and human melanoma cells. Cell Physiol Biochem. 1999; 9: 126–32.

37. Molitoris BA, Geerdes A, McIntosh JR. Dissociation and redistribution of Na+,K(+)-ATPase from its surface membrane actin cytoskeletal complex during cellular ATP depletion. J Clin Invest. 1991; 88: 462–9.

38. Barwe SP, Anilkumar G, Moon SY, et al. Novel role for Na,K-ATPase in phosphatidylinositol 3-kinase signaling and suppression of cell motility. Mol Biol Cell. 2005; 16: 1082–94.

39. Cappellen D, Schlange T, Bauer M, et al. Novel c-Myc target genes mediate differential effects on cell proliferation and migration. EMBO Rep. 2007; 8: 70–6.

40. Larriba MJ, Valle N, Pálmer HG, et al. The inhibition of Wnt/beta-catenin signaling by 1alpha, 25-dihydroxyvitamin D3 is abrogated by Snail1 in human colon cancer cells. Endocrinol Relat Cancer. 2007; 14: 141–51.

41. Espineda CE, Chang JH, Twiss J, et al. Repression of Na,K-ATPase beta1-subunit by the transcription factor Snail in carcinoma. Mol Biol Cell. 2004; 15: 1364–73.

42. Imamichi Y, Menke A. Signaling pathways involved in collagen-induced disruption of the E-cadherin complex during epithelial-mesenchymal transition. Cells Tissues Organs. 2007; 185: 180–90.

43. Robert G, Gaggioni C, Ballet O, et al. SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res. 2006; 66: 7516–23.

44. Onken MD, Ehlers JP, Worley LA, et al. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res. 2006; 66: 4602–9.

45. Sampson VB, Rong NH, Han J, et al. MicroRNA Let-7a down-regulates Myc and reverts Myc-induced growth in Burkitt Lymphoma cells. Cancer Res. 2007; 67: 9762–70.

46. Esquela-Kerscher A, Slack FJ. Oncomirs–microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6: 259–69.

47. Mendell JT. MicroRNAs. Critical regulators of development, cellular physiology and malignancy. Cell Cycle. 2005; 4: 1179–84.

48. Gaur A, Jewell DA, Liang Y, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007; 67: 2456–68.

49. Zhang L, Huang J, Yang N, et al. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA. 2006; 103: 9136–41.

50. Cummins JM, He Y, Leary RJ, et al. The colorectal microRNAome. Proc Natl Acad Sci USA. 2006; 103: 3687–92.